Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y P Liu

Showing results (281-290 of 287) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 287 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 13, 2023
[The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis]S J Zhong, J J Gao, P Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|June 12, 2020
[The phenotypes and genotypes in 314 patients with isolated methylmalonic acidemia]L L Kang, Y P Liu, M Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized studyY K Shi, L Wang, B H Han, et al.
Rhinology|October 30, 2023
Surgical treatment of nasopharyngeal cancer - a consensus recommendation from two Chinese associationsR You, Y P Liu, X Z Chen, et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|December 11, 2019
[Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists]L Li, L P Zhang, Y C Han, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III studyX Q Yan, M J Ye, Q Zou, et al.
Pageof 29

Showing results (281-290 of 287) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 287 results.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|February 13, 2023
[The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis]S J Zhong, J J Gao, P Tang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 26, 2019
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F Wang, X L Wei, F H Wang, et al.
Zhonghua Er Ke Za Zhi = Chinese Journal of Pediatrics|June 12, 2020
[The phenotypes and genotypes in 314 patients with isolated methylmalonic acidemia]L L Kang, Y P Liu, M Shen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized studyY K Shi, L Wang, B H Han, et al.
Rhinology|October 30, 2023
Surgical treatment of nasopharyngeal cancer - a consensus recommendation from two Chinese associationsR You, Y P Liu, X Z Chen, et al.
Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology|December 11, 2019
[Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists]L Li, L P Zhang, Y C Han, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III studyX Q Yan, M J Ye, Q Zou, et al.
Pageof 29